Sonrgy Taps A New CEO
2/13/2014 10:08:21 AM
Sonrgy Announces Key Management Recruits
SAN DIEGO--Sonrgy, Inc., a biotechnology company developing focused drug delivery technologies, has announced the appointment of key executives.
Brian O’Callaghan has been appointed as the company’s Chairman and CEO. Mr. O’Callaghan was most recently the CEO at Sangart, Inc., a San Diego-based pharmaceutical company. He brings 25 years of senior management experience in the life science sector, with companies that include NPS Pharmaceuticals, Covance, Novartis, BioPartners (co-founder), Merck, Pfizer, and Bayer. Mr. O’Callaghan holds an MBA from Henley College of Business Management in the UK and a Marketing Diploma from Cork Institute of Technology & Marketing Institute of Ireland.
In addition, David Renas is joining Sonrgy as Chief Financial Officer. Mr. Renas has a background in finance and law, having served as CFO and General Counsel at Sangart, as an attorney in private practice with Gray Cary Ware & Freidenrich (now DLA Piper) and Foley & Lardner, and as a CPA at Deloitte. Mr. Renas holds a Bachelor of Arts degree in Economics from Stanford University and a Juris Doctorate from the University of California at Davis.
These key recruits are aimed at helping the company execute on developing its first clinical drug candidate using Sonrgy’s proprietary SonRx delivery platform.
“I am delighted to join Sonrgy. This is a very promising technology with a real opportunity to address the need for precise drug delivery, particularly in the oncology space,” said Brian O’Callaghan. “I look forward to working with the founders to bring the SonRx technology to the clinic.”
About Sonrgy, Inc.
Sonrgy is a preclinical stage biotechnology company based in San Diego, California that is developing a targeted chemotherapy delivery platform to improve survival and quality of life for millions of cancer patients. Sonrgy’s tiny nanocarriers safely transport potent chemotherapy drugs to cancer tumors and release high doses on command in response to a focused beam of ultrasound. These carriers deposit drugs directly at the tumor cell sites, in order to avoid the many serious side effects of toxic chemotherapy circulating in the blood stream. Nanocarriers can deliver chemotherapy before surgery to reduce tumor size, after surgery to prevent recurrence and in situations when surgery is not possible to arrest tumor growth. This distinctive approach to delivering chemotherapy can be applied to many cancer tumors and enables more intensive treatment of the cancer, potentially improving effectiveness while reducing harmful effects on the rest of the body.
Brian O’Callaghan, 707-276-6749
Help employers find you! Check out all the jobs and post your resume.
comments powered by